Bioniche



August 25, 2010 Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology August 20, 2010 Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010
Check latest stock price All prices delayed at least 15 minutes. Source: TSX Inc.

Recent presentations and publications by Bioniche scientists and our research partners

David R. Smith, Rodney A. Moxley, Terry J. Klopfenstein, and Galen E. Erickson. A Randomized Longitudinal Trial to Test the Effect of Regional Vaccination Within a Cattle Feedyard on Escherichia coli O157:H7 Rectal Colonization, Fecal Shedding, and Hide Contamination. Foodborne Pathogens and Disease (Vol. 6, Number 7, 2009).
Rodney A. Moxley, David R. Smith, Matt Luebbe, Galen E. Erickson, Terry J. Klopfenstein, and Dragan Rogan. Escherichia coli O157:H7 Vaccine Dose-Effect in Feedlot Cattle. Foodborne Pathogens and Disease (Vol. 6, Number 7, 2009).
Alvaro Morales, Kiran Phadke, and Gary Steinhoff. Intravesical Mycobacterial Cell Wall-DNA Complex in the Treatment of Carcinoma In Situ of the Bladder After Standard Intravesical Therapy has Failed. Journal of Urology (Vol. 181, 1040-1045, March 2009).
David R. Smith, Rodney A. Moxley, Robert E. Peterson, Terry J. Klopfenstein, Galen E. Erickson, Gustavo Bretschneider, Emil M. Berberov, and Sharon Clowser. A Two-Dose Regimen of a Vaccine Against Type III Secreted Proteins Reduced Escherichia coli O157:H7 Colonization of the Terminal Rectum in Beef Cattle in Commercial Feedlots. Foodborne Pathogens and Disease (Vol. 6, Number 2, 2009).